From Lycia Therapeutics Prices Upsized IPO, Expected to Trade on Nasdaq

How could the SEC approval of Lycia Therapeutics' IPO affect TD Cowen?

Likely What happens if… A possibility worth considering, not a forecast.

TD Cowen may earn fees from Lycia Therapeutics' IPO As a joint book-running manager for the offering, TD Cowen is positioned to earn underwriting fees from Lycia Therapeutics' initial public offering. The offering involved 17,640,000 shares of common stock, priced at $18.00 per share, with gross proceeds expected to reach approximately $317.5 million. These fees represent a direct revenue stream for the investment bank based on facilitating the company's transition to public market trading.

Reported by 1 independent outlet Written Oct 23

Effect: Strong positive
How direct: Stated in the reporting
When: Right away
The story: Gone quiet

How it reaches TD Cowen

Reported by news outlets

TD Cowen is listed among the joint book-running managers for Lycia Therapeutics' upsized initial public offering. This offering involves 17,640,000 shares of common stock, which is expected to close on October 26, 2026.

1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- manilatimes.net Oct 1

Tap any step to see the evidence behind it.

The facts so far

As reported. Each one links to where it comes from.

Lycia Therapeutics is conducting an upsized initial public offering of 17,640,000 shares at an initial public offering price of $18.00 per share.manilatimes.net
TD Cowen is acting as a joint book-running manager for the offering.manilatimes.net
The gross proceeds from the offering are expected to be approximately $317.5 million.manilatimes.net

Why it matters

Underwriting fees are a primary source of revenue for major investment banks like TD Cowen. Successfully managing a large IPO, such as the one by Lycia Therapeutics, provides a significant, immediate boost to the bank's financial performance and reinforces its standing in the capital markets.

Biotechnology companies often rely on large public offerings to fund critical research and development. The involvement of major investment banks in these processes highlights the role of financial institutions in enabling the growth of the clinical-stage biotech sector.

What we don't know yet

What percentage of the gross proceeds will be allocated to underwriting fees?
How does this offering compare to other recent IPOs in the biotech sector?

What would change this answer

The offering closes successfully and meets its expected gross proceeds.The full underwriting fee structure will be realized, confirming the strong revenue impact for TD Cowen.

The offering faces significant delays or is scaled back.The final fee structure may be reduced, lessening the expected financial benefit for TD Cowen.

Who else could feel it

Other possible ripples from the same event.

NasdaqLikelyNasdaq could see increased trading volume and revenue from Lycia Therapeutics' IPO.

Reporting

manilatimes.netOct 1

Keep going

The full eventLycia Therapeutics Prices Upsized IPO, Expected to Trade on Nasdaq Everything aboutTD Cowen

Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.